Genetic Predictors of Benefit to Pembrolizumab
NCT02710396
Terminated
The primary objective is to determine if mutation load underlies sensitivity to pembrolizumab alone and in combination with chemotherapy. This will be a 3-arm, multi-center, open-label, non-randomized biomarker trial in patients with advanced, treatment-naive NSCLC. Patients will receive 1 of 3 possible cohorts as per investigator's discretion. Patients with non-squamous histology may receive any of the 3 cohorts; patients with squamous histology may receive either cohorts 1 and 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2023
Locations: Columbia University, New York, New York +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
NCT05794659
Not Yet Recruiting
The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: University of Washington, Seattle, Washington
Conditions: Advanced Ovarian Cancer
Register for Updates
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
NCT02530437
Terminated
This phase IB/II trial studies the side effects of taladegib, paclitaxel, carboplatin, and external beam radiation therapy and to see how well they work in treating patients with esophageal or gastroesophageal junction cancer found only in the tissue or organ where it began, and has not spread to nearby lymph nodes or to other parts of the body (localized). Taladegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage II Esophageal Adenocarcinoma AJCC v7, Stage IIA Esophageal Adenocarcinoma AJCC v7, Stage IIB Esophageal Adenocarcinoma AJCC v7, Stage IIIA Esophageal Adenocarcinoma AJCC v7, Stage IIIB Esophageal Adenocarcinoma AJCC v7
Register for Updates
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
NCT04572100
Completed
Doctors leading this study will give blood tests to head and neck cancer participants during the beginning of chemotherapy treatment (also known as induction therapy) to see if these blood tests can help predict tumor shrinkage after therapy and reduce the amount of additional radiotherapy or chemotherapy treatment the participant may need. This study will also examine ways to reduce overall side effects of treatment using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2023
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, amifostine, and peripheral stem cell transplantation in treating pat... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
07/03/2023
Locations: Cancer Center and Beckman Research Institute, City of Hope, Duarte, California
Conditions: Breast Cancer
Register for Updates
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
NCT03184870
Completed
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2023
Locations: Local Institution - 0003, Birmingham, Alabama +39 locations
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
NCT03573947
Completed
This is an open-label, non-randomized, phase II clinical research study designed to assess the safety and efficacy of nivolumab and ipilimumab in combination with paclitaxel in patients with treatment naïve NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Non-small Cell Lung Cancer
Register for Updates
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
NCT00003298
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells. E7296 was conducted to study neoadjuvant chemotherapy and postoperative chemoradiation therapy in patients diagnosed with high-risk gastric cancer using a new neoadjuvant regimen: paclitaxel plus cisplatin. It was hypothesized that t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado +29 locations
Conditions: Gastric Cancer
Register for Updates
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
NCT02560298
Active Not Recruiting
This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same place as the primary tumor, or spread to other places in the body. Drugs used in chemotherapy, such as cisplatin, fluorouracil, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania
Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Recurrent Anal Canal Carcinoma, Stage IIIB Anal Canal Cancer, Stage IV Anal Canal Cancer
Register for Updates
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
NCT00003518
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory metastatic germ cell tumors that have not responded to surgery or chemotherapy.
Gender:
ALL
Ages:
Between 15 years and 120 years
Trial Updated:
06/21/2023
Locations: CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado +18 locations
Conditions: Ovarian Cancer, Testicular Germ Cell Tumor
Register for Updates
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
NCT00003592
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate or paclitaxel is more effective in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of methotrexate with that of paclitaxel in treating patients who have advanced head and neck cancer that cannot be treated with cisplatin.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2023
Locations: Emory University Hospital - Atlanta, Atlanta, Georgia +19 locations
Conditions: Head and Neck Cancer
Register for Updates
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00062010
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Giving interferon alfa and isotretinoin together with paclitaxel may reduce resistance to the drug and allow the tumor cells to be killed. PURPOSE: This phase II trial is studying how well giving interferon alfa and isotretinoin together with paclitaxel works in treating patients with recurrent small... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia +72 locations
Conditions: Lung Cancer
Register for Updates